Clinical Trials Logo

Filter by:
NCT ID: NCT05734716 Completed - Clinical trials for Acute Mountain Sickness

Colorado-Oregon Altitude Study

COAST
Start date: February 17, 2021
Phase: Phase 4
Study type: Interventional

Investigating the utility of prophylactic treatment with iron sucrose and/or erythropoietin on the prevention of acute mountain sickness in fit, young, healthy individuals.

NCT ID: NCT05734443 Completed - Accidental Fall Clinical Trials

Trip Recovery Training Without a Specialized Treadmill

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to investigate the effects of a novel form of balance training called trip training. Trip training typically involves repeatedly exposing an individual to trip-like losses of balance on a specialized treadmill. This repeated exposure can lead to improvements in responses to trips while walking in the future, thereby reducing the risk of falling after a trip. Trip training typically is commonly conducted using a costly specialized treadmill. This study will evaluate the efficacy of a trip training protocol that does not require a treadmill. Adults age 65-80 will be assigned to either 1) non-treadmill trip training, 2) treadmill trip training, or 3) no intervention. The investigators hypothesized that responses to laboratory-induced trips would be better after non-treadmill trip training compared to no intervention, and that there would be no statistical difference between responses to laboratory-induced trips after non-treadmill trip training and treadmill trip training. The results from this work will advance the use of trip training, and may enable its wider use by establishing a protocol that does not require a costly treadmill.

NCT ID: NCT05734391 Completed - Clinical trials for Antimicrobial Resistance

Surveillance of Healthcare-associated Infections & Antimicrobial Resistance

Start date: October 1, 2022
Phase:
Study type: Observational

The aims of this project, called "Surveillance of Healthcare-associated infections & Antimicrobial Resistance", or "SHARE", are to 1) enhance laboratory capacity to detect emerging AMR patterns; 2) strengthen hospital epidemiology programs to use data to prevent, detect, and contain emerging AMR threats; 3) deploy study teams to answer critical public health surveillance questions, and 4) to build a national network of infection prevention and control (IPC) resources to prevent, detect, and contain emerging infectious disease threats

NCT ID: NCT05734235 Completed - Clinical trials for Ultraviolet B Radiation

UVB-Induced MVP Release in Human Skin

Start date: July 16, 2018
Phase: Phase 1
Study type: Interventional

This study is designed to assess if ultraviolet B radiation (UVB) found in sunlight causes the release of microvesicle particles in human skin, and if antioxidant vitamins can block their production.

NCT ID: NCT05733975 Completed - Clinical trials for Pediatric Critical Illness

Decision Making Support for Parents and Caregivers

Start date: May 2, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to test the feasibility and acceptability of a tool to support decision making for parents of critically ill infants.

NCT ID: NCT05733819 Completed - Parkinson Disease Clinical Trials

Responders to Rhythmic Auditory Cueing in Parkinson Disease

Start date: January 17, 2023
Phase: Phase 1
Study type: Interventional

Parkinson disease (PD) is the second most common neurodegenerative disease affecting approximately 10 million people worldwide. It is a complex movement disorder that results in reduced walking ability. Prior studies have identified declines in walking as a marker of ensuing disability. Rhythmic auditory stimulation (RAS) is a rehabilitation approach that employs the coupling of auditory cues with movement. Walking with RAS has been shown to benefit walking rhythmicity, quality, and speed. These walking benefits make RAS advantageous in promoting regular moderate-intensity walking activity -- an important health objective in the management of PD. However, there is limited research investigating the effects of RAS on walking quality and how improvements in walking speed are achieved. This study will enroll 30 individuals with mild to moderate PD where each participant will be asked to complete two six-minute walk tests, one standard test (baseline) and the other using an optimized metronome-based auditory cueing RAS intervention. The investigators hypothesize that individuals with PD will either walk farther or with more automaticity (i.e., reduced stride time variability) in the RAS condition compared to the baseline condition. Moreover, these walking improvements will be accompanied by improvements in gait mechanics and metabolic cost of walking.

NCT ID: NCT05733637 Completed - Anxiety Clinical Trials

HRAD-Vascular Access

Start date: June 8, 2023
Phase:
Study type: Observational

The perioperative setting is a common site of pediatric anxiety and distress. Perioperative anxiety in pediatric patients can result in uncooperative behavior, poor postoperative outcomes, and trauma. Given the fast-paced nature of the perioperative environment, many anxiety measures are too time consuming for clinical implementation prior to surgery. Pediatric anesthesiologists need reliable and efficient assessment tools to quickly measure childhood distress to target prophylactic and therapeutic interventions.

NCT ID: NCT05733455 Completed - Insulin Resistance Clinical Trials

Effect of Alpelisib in Healthy Volunteers

Start date: May 9, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to test a single dose of the phosphoinositide-3-kinase (PI3K) inhibitor alpelisib versus placebo in healthy volunteers. The main questions it aims to answer are the impact of acute alpelisib-induced insulin resistance on parameters of glucose and lipid metabolism (how healthy people respond to temporary insulin resistance so that the investigators can see what happens to how the liver handles fat and sugar). Participants will: - Consume their total calculated daily caloric needs in nutritional supplements, divided in three meals, and otherwise fast for 24 hours - Take a dose of alpelisib 300 mg or placebo at bedtime - Wear a continuous glucose monitor for 72 hours - Participate in an oral glucose tolerance test (OGTT) Researchers will compare blood tests before and during OGTT in participants randomized (like the flip of a coin) to alpelisib versus placebo to see how the drug treatment affects plasma glucose, serum insulin, and serum lipid parameters (triglycerides, free fatty acids, and apolipoprotein B).

NCT ID: NCT05733325 Completed - Clinical trials for Hypercholesterolemia

Diet-induced Elevations in LDL-C and Progression of Atherosclerosis

Keto-CTA
Start date: October 18, 2021
Phase:
Study type: Observational

This is an observational study examining the progression of subclinical coronary atherosclerosis in healthy participants who have an elevated LDL-C (above 190mg/dl) secondary to diet not associated with genetic familial hypercholesterolemia (FH). This study participants are classified to be Lean-Mass-Hyper-Responder (LMHR).

NCT ID: NCT05732740 Completed - Depression Clinical Trials

Empower@Home:Connected - Feasibility and Preliminary Effect Study

Start date: January 17, 2023
Phase: N/A
Study type: Interventional

This single-group trial will evaluate the feasibility and preliminary effect of a novel group-based cognitive behavioral therapy program for older adults with elevated depressive symptoms. Participants will complete the program remotely in small groups.